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It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of
low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties
in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics)
consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to
identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review
the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.
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BACKGROUND
Although inherited susceptibility underlies B35% of variance
in colorectal cancer (CRC) risk (Lichtenstein et al, 2000), high-
penetrance germline mutations account for o6% of cases
(Aaltonen et al, 2007). Much of the remaining variation in genetic
risk is likely to be a consequence of the co-inheritance of multiple
low-penetrance variants, some of which are common.
The ‘common-disease common-variant’ model of CRC implies
that association analyses based on scans of polymorphic variants
should be a powerful strategy for identifying low-penetrance
susceptibility alleles. This assertion has recently been vindicated
by genome-wide association (GWA) studies, which have provi-
ded robust evidence for several common low-risk variants
influencing CRC risk (Tomlinson et al, 2005, 2007; Broderick
et al, 2007; Zanke et al, 2007; Houlston et al, 2008; Jaeger et al,
2008; Tenesa et al, 2008). Although the risk of CRC associated
with each of these common variants is individually modest, they
make a significant contribution to the overall disease burden
by virtue of their high frequencies in the population. Moreover, by
acting in concert with each other, they have the potential to
significantly affect an individual’s risk of developing CRC.
Hence, this class of susceptibility alleles is potentially of public
health importance, allowing risk stratification within populations.
One benefit for risk prediction between population subgroups is
that it could enable tailoring of the invasiveness or frequency of
large bowel screening, eventually leading to a reduction in
mortality and even incidence through secondary prevention.
Finally, the identification of new risk variants may identify new
cancer pathways that made lead, in time, to the development of
new prevention or treatment strategies for CRC.
To facilitate the study of predisposition to CRC, we establis-
hed COGENT (COlorectal cancer GENeTics), an international
consortium with the goal of identifying and characterising
low-penetrance genetic variants that predispose to CRC. In this
study, we review the rationale for studying low-penetrance
susceptibility to CRC and our proposed strategy for COGENT.
Difficulties in conducting methodologically rigorous
association studies
To date, most association studies based on the candidate gene
approach have only evaluated a restricted number of polymor-
phisms, primarily in genes implicated in the metabolism of dietary
carcinogens and protection of DNA from carcinogen-induced
damage. Reports from these studies have largely been disappoint-
ing, with numerous positive associations initially from analyses
of small case–control series being unconfirmed by subsequent
analyses. Only a minority of studies have reported case–control
data on the same variants, allowing pooling of data (Table 1).
Although P-values from meta-analyses of such studies provide
limited support for the role of variants in MTHFR (Huang et al,
2007; Hubner and Houlston, 2007), CCND1 (Tan et al, 2008),
GSTT1 (de Jong et al, 2002), XPC (Zhang et al, 2008), NQO1
(Chao et al, 2006) and NAT2 (Chen et al, 2005), such analyses
should be interpreted with caution even if publication bias is
ignored. Use of false-positive report probability value (FPRP)
(Wacholder et al, 2004), which integrates the earlier probability for
association and statistical power, provides one method for
assessing the robustness of summary estimates derived from
pooled analyses. Although earlier probabilities are partly sub-
jective, influenced by previous findings and experimental evidence
with regard to the known impact of variants, the earlier probabi-
lity for variants in candidate genes is unlikely to be better than
1 in 1000 (or 0.001) (Thomas and Clayton, 2004). Imposing a
‘best case’ value less than 0.001 and stipulating an odds ratio
of 1.2 for associations, it is noteworthy that the likelihood of any
of the variants being associated with CRC risk is not high (i.e.,
FPRP 40.2 suggested to be appropriate for summary analyses
(Wacholder et al, 2004)). Hence, despite much research, until
the advent of GWA studies, few, if any, definitive susceptibility
alleles for CRC have been unequivocally identified through
association studies. The accumulated experience to date
has served to highlight the difficulties in conducting statistically
and methodologically rigorous association studies to identify
new cancer predisposition loci. The main issues are summarised
below:
1. The increase in CRC risk conferred by any common poly-
morphic variant is almost certainly small (i.e., typical relative
riskB1.2). The inherent statistical uncertainty of case–control
studies involving just a few hundred cases and controls severely
constrains study power to reliably identify genetic determinants
conferring modest, but potentially important, risks.
2. As of the large number of polymorphisms in the genome, false-
positive associations are inevitably more frequent than true-
positive associations when testing large numbers of generic
markers (especially when using off-the-shelf SNP arrays), even
if studies are conducted in a scientifically rigorous manner.
Hence, associations need to attain a high level of statistical
significance to be established beyond reasonable doubt. For this
reason, in GWA studies, a P-value threshold of 5.0 107 has
been advocated and is generally considered to be appropriate
for genome-wide significance.
3. Positive associations need to be replicated in independent
case–control series to further limit the type 1 error rate.
However, to increase power, the allelic architecture of the
population from which these case–control series are ascer-
tained needs to have similar ancestry and, ideally, the same
linkage disequilibrium (LD) structure.
4. It should be recognised that cancers such as CRC are somewhat
heterogeneous with respect to aetiology and biology. Specifi-
cally for CRC, colonic and rectal disease may have different risk
factors and have a varied spectrum of somatic mutations and
epimutations. It must thus be recognised that a given variant
may not affect the risk of all histological forms of CRC.
Table 1 Polymorphisms reported to be statistically significant in meta-analyses
Polymorphism Risk group
MAF/at risk
frequency OR (95% CI) P-value
No
studies/cases
Power,
OR¼ 1.2
FPRP @
prior of 0.001
CCND1-G870A GA vs GG 0.12–0.64 1.18 (1.06–1.32) 0.0031 12/4614 61% 0.86
GSTT1-null Null vs present 0.21–0.44 1.37 (1.17–1.60) 8.1 105 11/1490 5% 0.60
MTHFR-V222A TT vs CC 0.32–0.40 0.83 (0.75–0.93) 0.0007 25/12 261 47% 0.74
MTHFR A1298C CC vs CA+AA 0.29–0.22 0.81 (0.69–0.96) 0.012 14/4764 37% 0.98
NAT-acetylator Rapid vs slow 0.32–0.77 1.08 (1.00–1.16) 0.04 18/6741 99% 0.97
NQO1-Pro187Ser CT+TT vs CC 0.11–0.23 1.18 (1.02–1.35) 0.02 5/1637 60% 0.96
XPC lys939Gl CA vs AA 0.65–0.61 1.32 (1.11–1.56) 0.001 2/1060 13% 0.90
Abbreviations: CI¼ confidence interval; FPRP¼ false-positive report probability; MAF¼minor allele frequency; OR¼ odds ratio. Adapted from Dong et al (2008) and
Hubner and Houlston.
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The power of any analysis stratified by histology is therefore
limited because of the smaller numbers of cases in each group.
5. Careful attention must be paid to population stratification as a
source of confounding, because cancer rates and allele frequencies
vary with race/ethnicity. This is one possible explanation for some
of the false-positive associations reported in literature.
6. Epidemiological risk factor data should ideally be taken into
consideration to allow the examination of interactions between
known aetiological factors (e.g., dietary risk factors) and genetic
risk variants. As very large sample sizes are probably needed to
detect interactions, the power of these types of analyses in the
association studies reported to date has been extremely limited.
7. Rare germline polymorphisms may be more highly penetrant
and have significance for individuals, although the population-
attributable risk may be low. Extreme examples include the
previously identified mutations in DNA repair enzymes and
Lynch Syndrome. Only through genotyping and sequencing of
large numbers of individuals can additional rare variants that
confer important individual risk be identified. Advances in
sequencing technology make this feasible.
Characteristics of low-penetrance variants
Most studies aimed at identifying low-penetrance alleles for cancer
susceptibility have been based on a candidate gene approach
formulated on preconceptions of pathology pertaining to the role of
specific genes in the development of CRC. However, without a clear
understanding of the biology of predisposition, the choice of suitable
genes for the disease is inherently problematic, and very few suscep-
tibility loci for CRC have been identified that adopt this strategy.
An unbiased approach to genetic analysis is therefore required.
The availability of high-resolution LD maps and hence of
comprehensive sets of tagging SNPs that capture most of the
common sequence variation allows GWA studies for disease
associations to be efficiently conducted. This approach is agnostic
in that it does not depend on previous knowledge of function or
presumptive involvement of any gene in disease causation.
Moreover, it minimises the probability of failing to identify
important common variants in hitherto unstudied loci (i.e., genes
and regulatory regions).
Three GWA studies of CRC have so far been reported and 10
independent loci shown conclusively to be associated with CRC
risk: 8q24.21, 11q23, 18q21.1 (SMAD7), 8q23.1 (EIF3H), 15q
(GREM1), 19q13.1 (RHPN2), 20q12.3, 14q22.2 (BMP4), 16q22.1
(CDH1) and 10p14 (Tomlinson et al, 2005, 2007; Broderick et al,
2007; Zanke et al, 2007; Houlston et al, 2008; Jaeger et al, 2008;
Tenesa et al, 2008). Risks associated with each of the common
variants at each of these loci are modest (ORs 1.1–1.3; Table 2)
and there is little evidence of interactive effects. With homozygous
risk variants conferring twice the heterozygote risk, the distribu-
tion of risk alleles follows a normal distribution in both case and
controls, with a shift towards a higher number of risk alleles in
affected individuals consistent with a polygenic model of disease
predisposition (Figure 1A). Figure 1B shows the ORs relative to the
median number of risk alleles. Individuals with 15þ risk alleles
have at least a three-fold increase in risk compared with those with
a median number of risk alleles.
Data from these GWA studies and results from similar gene
discovery efforts in other tumours are proving to be highly
informative with regard to the allelic architecture of cancer
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Figure 1 Polygenic model of colorectal cancer susceptibility. (A)
Distribution of risk alleles for CRC, cases (black bars) and controls (grey
bars); (B) Plot of the increasing ORs for CRC with increasing number
of risk alleles. The ORs are relative to the median number of risk alleles;
Vertical bars correspond to 95% confidence intervals. Data from Houlston
et al (2008).
Table 2 The 10 loci associated with colorectal cancer risk identified from GWA studies (Tenesa and Dunlop, 2009)
Gene/locus Chromosome SNP
Effect size
(odds ratio)
Allele
frequency
Population
attributable risk (%)
— 8q24 rs6983267 1.21 (1.15–1.27) 0.51 9.7
GREM1 15q13 rs4779584 1.26 (1.19–1.34 0.18 4.5
SMAD7 18q21 rs4939827 1.18 (1.12–1.23 0.52 8.6
— 11q23 rs3802842 1.12 (1.07–1.17) 0.29 3.4
EIF3H 8q23 rs16892766 1.25 (1.19–1.32) 0.07 1.7
— 10p14 rs10795668 1.12 (1.10–1.16) 0.67 7.4
BMP4 14q21 rs4444235 1.11 (1.08–1.15) 0.46 4.8
CDH1 16q22 rs9929218 1.10 (1.06–1.12) 0.71 6.6
RHPN2 19q13 rs10411210 1.15 (1.10–1.20) 0.90 11.9
BMP2 20q12 rs961253 1.12 (1.08–1.16) 0.35 4.0
Abbreviation: GWA¼ genome-wide association.
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susceptibility in general. The number of common variants that
account for more than 1% of inherited risk is very low and only a
small proportion of the heritability of any cancer can be explained
by currently identified loci. Estimates of the contribution of
currently identified loci to excess familial risk of CRC may be
conservative, as there may be imperfect tagging surrogates for true
aetiological loci. Multiple causal variants may also exist at each
locus, including low-frequency variants with significantly larger
cumulative effects on risk. Few of the observed disease-associated
variants are coding variants, with many of the loci mapping to
regions bereft of genes or protein-encoding transcripts. It is likely
that much of the common variation in cancer risk is mediated
through sequence changes influencing gene expression, perhaps in
a subtle manner, or through effects on pathway components
mitigated by functional redundancy.
FUTURE DIRECTIONS
Prospects for identifying additional common variants
The power of existing GWA studies to identify common alleles
conferring risks of 1.2 or greater (such as the 8q24 variant) is high.
Hence, there are unlikely to be many additional CRC SNPs with
similar effects for alleles with frequencies 40.2 in populations of
European ancestry. Recent studies have had low power to detect
alleles with smaller effects and/or MAFs o0.1. By implication,
variants with such profiles are likely to collectively confer
substantial risk because of their multiplicity or sub-maximal LD
with tagging SNPs. The tagging SNPs used for GWA studies
capture on an average B80% of common SNPs in the European
population (i.e., r240.8), but only B12% of SNPs with MAFs of
5–10% are tagged at this level, limiting the power to detect this
class of susceptibility allele. GWA-based strategies are not
configured optimally to identify low-frequency variants with
potentially stronger effects or to identify recessively acting alleles.
Nor are current arrays formatted ideally to capture copy number
variants or other structural variants such as small-scale insertions
or deletions, which may affect CRC risk. It is therefore highly likely
that a large number of low-penetrance variants remain to be
discovered. This assertion is supported by the continued excess of
associations observed over those expected in studies reported to
date. Further efforts to expand the scale of GWA meta-analyses, in
terms of both sample size and SNP coverage, and to increase the
number of SNPs taken forward to large-scale replication may
identify additional variants for CRC.
Analyses of most GWA studies have so far been primarily
directed towards identifying single locus SNP associations. It is
possible that analyses based on haplotypes of markers may identify
‘rarer’ disease alleles that may be present on rare haplotypes
missed by single SNP analyses. Under certain circumstances,
especially in which interaction effects are large and main effects are
small, gene–gene interactions may be detected where no locus
with a main effect has been identified (Marchini et al, 2005). Multi-
locus approaches may therefore be the focus of future experiments
as they may yield greater power to detect associations under
certain genetic models.
Identifying causal variants
Validated tagSNPs are highly unlikely to directly cause CRC.
Identifying the causal variant from a tagSNP that is statistically
associated with disease is difficult. Although blocks of LD allow the
efficient survey of the genome, they hamper fine mapping of the
disease-associated region. Different ethnic groups are likely to
have different LD block patterns and they can therefore be used to
refine the location of a disease susceptibility locus before
resequencing and functional analyses. The usefulness of this
approach depends on the size of the study and SNP allele
frequencies in different ethnic groups. In some of these popula-
tions, lower environmental risk exposure with lower CRC,
incomplete case ascertainment and recording tools, as well as
absence of large sample sets, are other challenges.
Incorporating non-genetic risk factors into risk models
Colorectal cancer risk will probably be determined by complex
interactions between the various genetic and lifestyle/dietary risk
factors. Epidemiological studies have established several dietary
risk factors for colorectal neoplasia; these include low vegetable
and high meat consumption (especially processed meat), and
micronutrient deficiency and excessive alcohol intake. There is a
weaker association between CRC, smoking and lack of physical
activity. Common genetic variants are likely to interact with these
environmental– lifestyle risk factors to modify risk. Furthermore,
common gene variants will have a role in determining the
effectiveness of chemoprevention agents such as non-steroidal
anti-inflammatory drugs, hormone replacement therapy and
micronutrient supplementation.
In assessing the interplay between inherited and non-genetic
risk factors, analyses using different population cohorts will be
highly informative. Wider comparisons between the population
genetics of different ethnic groups have shown that SNP allele
frequencies can vary greatly among ethnic groups, principally as
a result of founder effects and genetic drift. Indeed, some SNPs
may be informative in one population and not in another. At least
in principle and probably in practice, some variants may have
stronger or weaker effects on disease, depending on environment
or general genetic background, as observed in inbred lines of mice.
Identification of the interaction between genetic variants and
environmental risk factors is contingent on very large data sets
ideally from different population cohorts, something only achiev-
able through multi-centre collaborations. Even with such colla-
borative efforts, incorporating environmental risk factor data into
models of predisposition is likely to be a serious challenge as,
although ethnicity can be defined through genotype, environ-
mental background is harder to standardise.
Inherited prognostic and predictive variants
In addition to influencing the risk of developing CRC, inherited
genetic host factors are likely to influence the natural course of the
disease. As a potential prognostic factor, the concept of germline
variation imparting inter-individual variability in tumour devel-
opment, progression and metastasis is receiving increasing
attention. Compared with breast cancer, studies of the impact of
germline variation on CRC prognosis have been more limited.
Prognostic studies have generally examined the same candidate
genes that are considered to have a role in predisposition.
Genetic variation affecting inter-individual disease expression
may influence the later stages of malignancy rather than early
events associated with an inherited predisposition. Variants in
growth factor, apoptosis or immune surveillance signalling
pathways, for instance, might not cause CRC initiation but could
have a substantial effect on the outcome of established disease.
Chemotherapy response and toxicity may be related to germline
genotype. Linking GWA data to patient outcome provides an
attractive strategy for identifying new prognostic markers. It is
essential to impose appropriate statistical thresholds and conduct
replication analyses to avoid reporting false positives.
RATIONALE FOR THE COGENT CONSORTIUM
The recognition that low-penetrance alleles contribute to the
inherited risk of CRC represents a major advance in our
Colorectal cancer association consortium
IPM Tomlinson et al
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Table 3 Number of CRC cases and controls currently established by COGENT consortium members
Number of
subjects
European Study name General setting Cases Controls
Institute of Cancer Research, UK NSCCG (National Study of Colorectal Cancer)
(Penegar et al, 2007)
Population-based UK study. Spouse controls from
NSCCG (Penegar et al, 2007) and GELCAPS
(Genetic Lung Cancer Predisposition Study)
(Eisen et al, 2008)
12 976 6000
Edinburgh University, UK COGS (Colorectal Cancer Genetics Susceptibly Study)
(Porteous et al, 2003)
Population-based incident case series aged o55 at
diagnosis. Population-based controls
1012 1012
SOCCS (Scottish Colorectal Cancer Study)
(Theodoratou et al, 2008)
Population-based incident case series; Scotland, UK 3000 3000
Oxford University, UK CORGI (Colorectal Tumour Gene Identification
Consortium) (Kemp et al, 2006)
Cases with family history of CRC ascertained
through clinical genetics centres in the UK. Spouse
controls with no personal or family history of CRC
940 965
VICTOR – post-treatment stage of a Phase III,
randomised double-blind, placebo-controlled study of
rofecoxib (VIOXX) in colorectal cancer patients after
potentially curative therapy (Kerr et al, 2007)
Samples from a closed clinical trial 910 —
QUAZAR2 – multicentre international study of
capecitbine+/bevacizumab as adjuvant treatment of CRC
UK blood donors 139 376
Cambridge University, UK SEARCH (Studies of Epidemiology and Risk Factors in
Cancer Hereditary)
Population-based case–control study; Cambridge,
UK
3000 3000
Barcelona and Santiago, Spain EPICOLON Consortium (Castells and Andreu, 2007) Population-based case–control study; Spain 2000 2000
Barcelona, Spain ENTERICOS (Disinfection by-products and other
Environmental, genetic and molecular determinants of
colorectal cancer – subproductos de la desinfeccio´n y
otros determinantes ambientales, gene´ticos y
moleculares del ca´ncer colorectal en Espan˜a)
Case–control study of CRC to evaluate the
increased risk associated with chronic DBP
exposure through ingestion, inhalation and dermal
absorption
500 500
Bellvitge Case–Control Study 370 325
University of Helsinki, Finland FCCPS (Finnish Colorectal Cancer Predisposition
Study) (Salovaara et al, 2000)
Population-based study; South-eastern Finland 1440 2000
Karolinska Institute, Sweden Unselected cases ascertained through 12 hospitals
serving the Stockholm-Gotland and Uppsala-
O¨rebro health-care regions in Sweden. Blood
donor controls
3000 3000
German Cancer Research
Centre (DKFZ): on behalf of
German HNPCC consortium
German HNPCC consortium (Frank et al, 2008) Familial non-HNPCC cases recruited through
German HNPCC consortium, principally through
six hospitals of Bochum, Bonn, Dresden,
Du¨sseldorf, Heidelberg and Munich/Regensburg.
Controls: unrelated and ethnicity- and age-matched
blood donors recruited by the Institute of
Transfusion Medicine and Immunology, Faculty of
Mannheim, Germany
1000 1000
University of Keil and
Greifswald, Germany
POPGEN (Population Genetic Cohort) from
Schleswig-Holstein, north Germany (Krawczak et al,
2006; Schafmayer et al, 2007). SHIP (Survey of Health
in Pommerania) from east and north-east Germany
(Volzke et al, 2005)
Population-based biobank projects 2720 2720
German Cancer Research
Centre
ESTHER (Epidemiologische Studie zu Chancen der
Verhu¨tung, Fru¨herkennung und optimierten Therapie
chronischer Erkrankungen in der a¨lteren Bevo¨lkerung)
Population-based biobank project 670 670
Institute of Experimental
Medicine, Academy of Science,
Czech Republic
— Unselected CRC cases mainly recruited from nine
oncological departments (Prague, Benesov, Brno,
Liberec, Ples, Pribram, Usti nad Labem and Zlin)
(Tulupova et al, 2008). Controls hospital patient
and blood donors
1300 3000
University of Groningen, the
Netherlands
SCOPE study (de Jong et al, 2005) Unselected CRC cases, hospital patient controls
from the Netherlands
774 1000
University of Leiden, the
Netherlands
Unselected CRC cases. Controls ascertained
through genetic testing programmes for non-
cancer-related conditions
1500 1500
Fondazione IRCCS Istituto
Nazionale Tumori, Milan, Italy
Unselected CRC cases, population controls 700 1200
Australia
Ludwig Institute for Cancer
Research, Melbourne
Victorian Cancer Biobank Population-based biobank project 1000 500
The University of Newcastle,
New South Wales
Hunter Family Cancer Service Population-based collection of cases and controls
from the Hunter Region of New South Wales
600 3000
Table continued overleaf
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understanding. In view of the above-noted issues, over the last few
years, collaborations have been steadily developing between
groups in the United Kingdom, Canada, the Americas, Holland,
Germany, Finland, Spain and Australia that are engaged in
ongoing searches for low-penetrance CRC variants through
association-based studies. What initially began from relatively
loose affiliations centred around work on specific projects has
begun to crystallise into a more formal collaborative network after
replication analyses of two published GWA studies. To continue
and expand collaboration, a meeting was held at the University of
Leiden, the Netherlands, in January 2009 to review ongoing
association studies. There assembled an international team of
researchers with expertise encompassing genetic epidemiology,
statistical genetics, gene mapping, biology, molecular genetics,
pathology and diagnosis and clinical management of CRC.
There was a consensus among participants that many of the
challenges inherent in this field can best be addressed by
international cooperative efforts, and the group unanimously
decided to establish a CRC association consortium. An invitation
to join COGENT that was subsequently extended to other groups
known to be performing CRC association studies was well
received. At present, 20 groups that are performing case–control
genetic association studies have joined COGENT (Table 3).
The eligibility criterion for inclusion is the involvement in a
case–control study based on at least 500 cases and 500 controls
sampled from the same population. The sample size limit
aims to ameliorate the potential statistical, biological and
technological/methodological confounding effects of small sample
sizes (Moonesinghe et al, 2008). Collectively, over 48 000 cases
and 43 000 controls have so far been accrued by COGENT
researchers (Table 3).
In each of the study centres, collection of samples and of clinico-
pathological information has been undertaken with informed
consent and relevant ethical review board approval in accordance
with the tenets of the Declaration of Helsinki. Material transfer
agreements have already been used between partners to allow for
sharing of individualised data, and similar procedures will be
adopted for future collaborative work.
Data pooling provides a very cost-effective approach to achieve
an adequate power for subgroup analyses, which are unlikely to
have sufficient sample sizes in a single study. Several potential
problems need to be considered at the stage of data pooling. Given
that individual studies have different data formats, covariates from
individual studies will be agreed upon and compiled into a
common set of variables relevant to specific projects. Study data
sets sent from different centres will be checked for outliers,
aberrant distribution, inadmissible values and inconsistencies
before pooling to ensure data accuracy. Systematic variation
between centres in terms of genotyping will be assessed globally
using principal components and on a per-SNP basis. Discrepancies
can be cross-verified with study centres.
COGENT represents the first international collaborative study
seeking to comprehensively understand the impact of low-
penetrance susceptibility to CRC and to describe the genetic
landscape of the disease. The immediate goal of the group is to
work together collaboratively to study polymorphisms that were
previously associated with CRC risk and to plan for future high-
quality studies. Past productive collaboration has laid the ground-
work for these future studies centred initially on the expansion of
discovery and replication of GWA studies, with biological analyses
of variants and epidemiological studies as longer-term aims.
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European Study name General setting Cases Controls
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Toronto, Canada OFCCR (Ontario Familial Colorectal Cancer Registry)
(Cotterchio et al, 2000)
Population-based case–control study; Ontario 1257 1336
Asia
University Hong Kong
Medical Centre, China
UHKMC series Unselected CRC cases, hospital patient controls 2000 2000
University of Tokyo, Japan Biobank Japan Population-based biobank project 6000 6000
Total 49 308 46 804
Abbreviations: COGENT¼COlorectal cancer GENeTics; CRC¼ colorectal cancer.
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health-c
Biobank Japan – http://www.src.riken.go.jp/english/project/person/
index.html
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National Study of Colorectal Cancer Genetics (NSCCG) – http://
www.icr.ac.uk/research/research_sections/cancer_genetics/cancer_
genetics_teams/molecular_and_population_genetics/nsccg/index.
shtml
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